Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Código QR

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Richard A Chudleigh,1 Julia Platts,2 Stephen C Bain1,3 1Singleton Hospital, Swansea Bay University Health Board, Swansea, UK; 2Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK; 3Diabetes Research Unit Cymru, Swansea University Medical School, Swan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chudleigh RA, Platts J, Bain SC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	type 2 diabetes glp-1 receptor agonists long-acting glp-1ras Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a62ddcdd92ec4bee901c150944eab50a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
por: Yanbin Dong, et al.
Publicado: (2021)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson AM, et al.
Publicado: (2016)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Toomas Jagomäe, et al.
Publicado: (2021)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
por: Lee SP, et al.
Publicado: (2019)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

Activation of the GLP-1 receptor by chloropyrimidine derivatives
por: Shaikha S. AlNeyadi, et al.
Publicado: (2021)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Masao Koike, et al.
Publicado: (2021)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes
por: Pan X, et al.
Publicado: (2019)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
por: Liu F, et al.
Publicado: (2020)

Associations of TCF7L2 rs11196218 (A/G) and GLP-1R rs761386 (C/T) Gene Polymorphisms with Obesity in Chinese Population
por: Xu T, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
por: Kutoh Eiji, et al.
Publicado: (2019)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin AA, et al.
Publicado: (2016)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Role of incretin based therapies in the treatment of diabetic kidney disease
por: Paola Fioretto, et al.
Publicado: (2018)

Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
por: A Pegah, et al.
Publicado: (2021)

Activation of ectopic olfactory receptor 544 induces GLP-1 secretion and regulates gut inflammation
por: Chunyan Wu, et al.
Publicado: (2021)

The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity
por: Daria A. Skuratovskaia, et al.
Publicado: (2019)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
por: Hui Li, et al.
Publicado: (2021)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by <named-content content-type="genus-species">Enterococcus faecalis</named-content> Metalloprotease GelE
por: Stephanie L. LeValley, et al.
Publicado: (2020)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le TD, et al.
Publicado: (2020)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells
por: Ma L, et al.
Publicado: (2020)

Diseño y Evaluación de Mezcladores de un Quemador Doméstico usando Gas Licuado de Petróleo
por: Rojas,Freddy J, et al.
Publicado: (2017)